a Department of Hematology , Jagiellonian University Medical College , Cracow , Poland.
b Department of Hematology , Hospital Universitario de Salamanca , Salamanca , Spain.
Leuk Lymphoma. 2019 Feb;60(2):471-476. doi: 10.1080/10428194.2018.1480766. Epub 2018 Jul 22.
A small proportion of patients with multiple myeloma (MM) are diagnosed at a very young age. The clinicopathological characteristics and prognosis of these patients are not well known. This analysis included 52 patients diagnosed with MM at the age of ≤30 years (range: 8-30 years). 68% of patients had International Scoring System (ISS) 1 MM; 22% presented with the light chain-only disease, and 48% with elevated serum lactate dehydrogenase (LDH). 85% of patients were treated with novel agents, and 62% received front-line autologous stem cell transplantation (ASCT). Overall response rate (ORR) to front-line treatment and ASCT were 71% and 90%, respectively. The group was followed-up for the median period of 86 months. The median overall survival (OS) was 166 months (95% CI: 53-222), with 5-year OS rate of 77% (95% CI: 61.0-87.9). This findings suggest that the prognosis in young MM patients may be as good if not better than in the general population of MM patients.
一小部分多发性骨髓瘤（MM）患者在非常年轻的时候被诊断出来。这些患者的临床病理特征和预后尚不清楚。本分析纳入了 52 例≤30 岁（范围：8-30 岁）诊断为 MM 的患者。68%的患者具有国际预后评分系统（ISS）1 MM；22%为单克隆轻链型，48%血清乳酸脱氢酶（LDH）升高。85%的患者接受了新型药物治疗，62%接受了一线自体造血干细胞移植（ASCT）。一线治疗和 ASCT 的总缓解率（ORR）分别为 71%和 90%。该组的中位随访时间为 86 个月。中位总生存期（OS）为 166 个月（95%CI：53-222），5 年 OS 率为 77%（95%CI：61.0-87.9）。这些发现表明，年轻 MM 患者的预后可能与 MM 患者的一般人群一样好，如果不是更好的话。
